Cumberland Pharmaceuticals Inc Reports Q3 2024 Revenue of 9.1 Million and EPS Loss of 0.11
| 034863BA7 | 84.81 2.31 2.65% |
About 62% of AALLN's investor base is looking to short. The analysis of the overall prospects from investing in AALLN 2875 17 MAR 31 suggests that many traders are, at the present time, alarmed. The current market sentiment, together with AALLN's historical and current headlines, can help investors time the market. In addition, many technical investors use AALLN 2875 17 bond news signals to limit their universe of possible portfolio assets.
AALLN |
Revenue Achieved 9.1 million in net revenues for Q3 2024, with year-to-date revenues totaling 27 million.Net Loss Reported a net loss of 1.5 million for Q
Read at gurufocus.com
 |
AALLN 2875 17 Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with AALLN bond to make a market-neutral strategy. Peer analysis of AALLN could also be used in its relative valuation, which is a method of valuing AALLN by comparing valuation metrics with similar companies.
Peers
AALLN Related Equities
| SQFT | Presidio Property | 16.33 | ||||
| XPOF | Xponential Fitness | 3.97 | ||||
| NVNO | EnVVeno Medical | 3.33 | ||||
| NUVL | Nuvalent | 2.37 | ||||
| ALVO | Alvotech | 0.16 | ||||
| CPIX | Cumberland Pharmaceuticals | 1.85 | ||||
| CNTA | Centessa Pharmaceuticals | 6.32 |
Other Information on Investing in AALLN Bond
AALLN financial ratios help investors to determine whether AALLN Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AALLN with respect to the benefits of owning AALLN security.